Ayala Pharmaceuticals is Biotechnology in United States that focus on stage oncology company business. Founded in 2017. They cover business area such as Ayala Pharmaceuticals Inc clinical-stage oncology company, small molecule therapeutic, patient, rare and aggressive cancer, product candidate, gamma-secretase inhibitor, GSI, t-ALL, an aggressive, rare form, t-cell-specific leukemia.
2017
( 7 years old in 2024 )
Stage Oncology Company
-
1007 North Orange Street
4th Floor
Wilmington, DE 19802
United States
Private
Ayala Pharmaceuticals Inc clinical-stage oncology companysmall molecule therapeuticpatientrare and aggressive cancerproduct candidategamma-secretase inhibitorGSIt-ALLan aggressive, rare formt-cell-specific leukemia
* We use standard office opening hours in near Ayala Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ayala Pharmaceuticals is Biotechnology business from United States that founded in 2017 (7 years old in 2024), Ayala Pharmaceuticals business is focusing on Stage Oncology Company.
Ayala Pharmaceuticals headquarter office and corporate office address is located in 1007 North Orange Street 4th Floor Wilmington, DE 19802 United States.
Ayala Pharmaceuticals was founded in United States.
In 2024, Ayala Pharmaceuticals is currently focus on stage oncology company sector.
Above is snippet of Google Trends for "stage oncology company" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ayala Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
